Syri Limited, T/A SyriMed is recalling batches of product as a precautionary measure due to crystallisation observed over time in the oral solution.
Similar Posts
Fast, Expert and Open – how the MHRA is poised to become a global leader in risk-proportionate regulation
New MHRA CEO puts safety, accelerated access and innovation at the centre of agency’s refreshed strategic direction.
MHRA approves UK’s first anti-PD-1 monoclonal antibody for treatment of aggressive form of lung cancer
As with all products, we will keep its safety under close review
Decision: Advertising Investigations: December 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Variations to marketing authorisations (MAs)
How the MHRA processes variations to marketing authorisations.
Decision: Advertising Investigations: May 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Designated standards prioritisation
The MHRA invite feedback on the use of designated standards for medical devices and in vitro diagnostic (IVD) devices to help shape future initiatives.